HC Wainwright Lowers Zura Bio (NASDAQ:ZURA) Price Target to $3.00

Zura Bio (NASDAQ:ZURA) had its price objective cut by equities researchers at HC Wainwright from $5.00 to $3.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. HC Wainwright’s price target points to a potential upside of 191.26% from the stock’s current price.

Several other analysts have also issued reports on ZURA. Oppenheimer reiterated an “outperform” rating and set a $19.00 price objective (down from $20.00) on shares of Zura Bio in a report on Wednesday, March 26th. Chardan Capital cut their price target on Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, March 26th. Guggenheim reissued a “buy” rating and issued a $15.00 price target on shares of Zura Bio in a research note on Wednesday, March 26th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Zura Bio has a consensus rating of “Buy” and an average target price of $14.67.

Zura Bio Trading Down 5.1 %

Shares of Zura Bio stock opened at $1.03 on Thursday. Zura Bio has a 1 year low of $0.97 and a 1 year high of $6.35. The company has a market cap of $67.25 million, a P/E ratio of -1.94 and a beta of 0.08. The stock has a 50-day moving average price of $1.40 and a 200 day moving average price of $2.65.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Tuesday, March 25th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.09. The company had revenue of $0.00 million for the quarter. On average, equities analysts forecast that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Zura Bio

Institutional investors have recently modified their holdings of the company. American Century Companies Inc. bought a new position in shares of Zura Bio in the fourth quarter worth about $27,000. Prudential Financial Inc. acquired a new position in shares of Zura Bio during the fourth quarter worth approximately $28,000. Two Sigma Advisers LP bought a new stake in shares of Zura Bio in the fourth quarter valued at approximately $32,000. ProShare Advisors LLC acquired a new stake in shares of Zura Bio in the fourth quarter worth $35,000. Finally, XTX Topco Ltd bought a new position in Zura Bio during the fourth quarter worth $44,000. Institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.